{"protocolSection":{"identificationModule":{"nctId":"NCT03318783","orgStudyIdInfo":{"id":"17614"},"organization":{"fullName":"Oregon Health and Science University","class":"OTHER"},"briefTitle":"Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial","officialTitle":"Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial","acronym":"SUSHI"},"statusModule":{"statusVerifiedDate":"2020-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-05-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-04-03","type":"ACTUAL"},"completionDateStruct":{"date":"2020-01-09","type":"ACTUAL"},"studyFirstSubmitDate":"2017-10-10","studyFirstSubmitQcDate":"2017-10-18","studyFirstPostDateStruct":{"date":"2017-10-24","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-10-01","resultsFirstSubmitQcDate":"2020-12-31","resultsFirstPostDateStruct":{"date":"2021-01-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-12-31","lastUpdatePostDateStruct":{"date":"2021-01-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ross Martini, MD","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Oregon Health and Science University"},"leadSponsor":{"name":"Oregon Health and Science University","class":"OTHER"},"collaborators":[{"name":"Foundation for Anesthesia Education and Research","class":"OTHER"},{"name":"GlaxoSmithKline","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Soluble epoxide hydrolase (sEH) is the metabolizing enzyme of epoxyeicosatrienoic acids (EETs), which may play a role in reducing neuroinflammation and regulating cerebral blood flow after subarachnoid hemorrhage (SAH). Hypotheses: Pharmacologic inhibition of the sEH enzyme is safe and will result in increased EETs availability in the blood and cerebrospinal fluid. This study is a double-blind, placebo-controlled, phase 1b randomized trial to evaluate the safety and efficacy of GSK2256294, a novel soluble epoxide hydrolase inhibitor in patients with aneurysmal SAH.","detailedDescription":"Study Description: Soluble epoxide hydrolase (sEH) is the metabolizing enzyme of epoxyeicosatrienoic acids (EETs), which may play a role in reducing neuroinflammation and regulating cerebral blood flow after subarachnoid hemorrhage (SAH).\n\nHypothesis: Pharmacologic inhibition of the sEH enzyme is safe and will result in increased EETs availability at the neurovascular unit, and a measured increase in the EET/DHET ratio in the serum and cerebrospinal fluid. This study is a double-blind, placebo-controlled, phase 1b randomized trial to evaluate the safety and of GSK2256294, an inhibitor of soluble epoxide hydrolase, in patients with aneurysmal SAH.\n\nObjectives:\n\nPrimary Objective:\n\nDetermine the safety of administration of GSK2256294 in patients with aneurysmal SAH.\n\nSecondary Objective:\n\nDetermine the pharmacodynamic effect of administration of GSK2256294 in patients with aneurysmal SAH on reducing EETs metabolism and biomarkers of cerebrovascular inflammation and endothelial injury.\n\nTertiary Objective:\n\nProvide preliminary estimates of clinical endpoints to inform the design of a larger trial\n\nEndpoints:\n\nPrimary Endpoints:\n\nDetermination of safety\n\nSecondary endpoints:\n\n1. Study days 7 and 10 serum EET/DHET ratios\n2. Study days 7 and 10 cerebrospinal fluid (CSF) EET/DHET ratios\n3. Study days 7 and 10 serum EPOME/DPOME ratio\n4. Neuroinflammatory and endothelial injury biomarker levels from the blood and CSF at day 7 and day 10.\n\nTertiary, exploratory endpoints:\n\nClinical outcomes associated with SAH including neurologic status, disposition, vital status and incidence of delayed cerebral ischemia.\n\n20 subjects will be randomized. Patients age 18 or above with confirmed ruptured aneurysms will be approached to provide written informed consent\n\nPhase: Phase 1B\n\nDescription of Sites/Facilities Enrolling Participants: The study will take place at Oregon Health \\& Science University Hospital, with enrollment of patients admitted to the OHSU NSICU, a part of a comprehensive stroke center certified by the American Heart Association and Joint Commission for Accreditation of Healthcare Organizations, with a catchment area including the state of Oregon, Southwest Washington and Northern California. Approximately 80-100 patients with aneurysmal SAH are admitted each year.\n\nDescription of Study Intervention: Twenty patients will be equally randomized to receive once daily either 10 mg dose of GSK2256294 or placebo enterally for a duration of 10 days.\n\nStudy Duration: 24 months\n\nParticipant Duration: 90 days"},"conditionsModule":{"conditions":["Subarachnoid Hemorrhage, Aneurysmal","Delayed Cerebral Ischemia","Vasospasm, Cerebral","Endothelial Dysfunction"],"keywords":["Eicosanoids","Epoxyeicosatrienoic Acids"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Subjects will be randomized to one of the two treatment arms based on an unrestricted or \"fair-coin\" randomization procedure.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Investigational pharmacy staff will maintain the randomization list and study/drug placebo assignment. Participants, care providers, the investigators and outcomes assessors will be blinded to the grouping.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":20,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"GSK2256294","type":"ACTIVE_COMPARATOR","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.","interventionNames":["Drug: GSK2256294"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"GSK2256294","description":"GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.","armGroupLabels":["GSK2256294"]},{"type":"DRUG","name":"Placebo","description":"Placebo will be administered in a single dose once daily enteral for a duration of 10 days.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Participants With Adverse Events","description":"Summary tables and listings will be provided for all reported adverse events, defined as adverse events that start on or after the first administration of study drug. The reported adverse event term will be assigned a standardized preferred term.\n\nAdverse events will be summarized based on the number and percentage of patients experiencing the event. In the event a patient experiences repeat episodes of the same adverse event, then the event with the highest severity grade and strongest causal relationship to study treatment will be used for purposes of incidence tabulations.\n\nAll deaths will be reported in a patient listing, which will include the primary cause of death and the number of days between the date of the last dose of study drug and death.","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"Study Day 7 and Study Day 10 Serum and CSF EET/ Dihyroxyeicosatrienoic (DHET) Ratio, by Mass Spectroscopic Analysis (ng/mL)","description":"Day 7 and day 10 serum EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected blood samples.\n\nDay 7 and day 10 CSF EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected CSF samples.","timeFrame":"10 days"},{"measure":"Study Day 7 and Study Day 10 Serum Epoxyoctadecenoic Acid (EPOME) to Dihydroxyoctadec-12-enoic Acid (DPOME) Ratio, by Mass Spectroscopic Analysis (ng/mL)","description":"Study day 7 and study day 10 serum epoxyoctadecenoic acid (EPOME) to dihydroxyoctadec-12-enoic acid (DPOME) ratio, will be measure by mass spectroscopic analysis of collected blood samples.","timeFrame":"10 days"},{"measure":"Serum Biomarkers of Endothelial Injury From Blood Samples Obtained on Study Day 7 and Study Day 10","description":"The following serum biomarkers will be obtained from collected blood samples by Luminex assay: e-selectin, p-selectin, Vascular cell adhesion marker (VCAM-1), Platelet endothelial cell adhesion marker (PECAM-1, CD31), intercellular adhesion molecule (ICAM-1).","timeFrame":"10 days"},{"measure":"CSF Biomarkers of Neuroinflammation, From Blood Samples Obtained on Study Day 7 and Study Day 10","description":"The following CSF biomarker will be obtained from collected CSF samples by Luminex assay: Tumor necrosis factor alpha (TNF-α) (pg/mL), Interleukin 1β (IL-1β) (pg/mL), Interferon gamma (IFN-γ) (pg/mL), Interleukin 6 (IL-6) (pg/mL), Interleukin 8 (IL-8) (pg/mL), Monocyte chemoattractant protein 1 (MCP-1) (pg/mL)","timeFrame":"10 days"}],"otherOutcomes":[{"measure":"Hospital Length of Stay in Days","description":"The hospital length of stay will be recorded in days, at the time of hospital discharge.","timeFrame":"90 days"},{"measure":"Discharge Disposition","description":"The disposition from the hospital in one of the following categories: home, home with services, rehab, long term acute care facility, skilled nursing facility, hospice, death","timeFrame":"90 days"},{"measure":"Number of Participants With New Stroke on Hospital Discharge Imaging","description":"The last head CT or other brain imaging to detect the presence of a new area of cerebral infarction will be reviewed at the time of hospital discharge. A cerebral infarction will be defined as a one identified on hospital discharge that was not present on imaging between 24-48 hours after aneurysm occlusion, and not attributable to other causes such as surgical clipping or endovascular treatment. Hypodensities resulting from extraventricular drains or residual intraparencyhmal hematomas will not be considered new strokes.","timeFrame":"90 days"},{"measure":"Modified Rankin Scale (mRS) at Hospital Discharge and 90 Day Follow up","description":"The mRS score will be determined by patient or surrogate interview, at both hospital discharge and 90 day follow up. Scores will be assigned based on the following: 0 - no symptoms, 1 - no significant disability, able to carry out all usual activities despite some symptoms, 2 - slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 - moderate disability, requires some help, but able to walk unassisted, 4 - moderately severe disability, unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 - severe disability, requires constant nursing care and attention, bedridden, incontinent, 6 - deceased.","timeFrame":"90 days"},{"measure":"Extended Glasgow Outcome Scale (GOSE) Score at 90 Day Follow up","description":"At 90 day follow up, the GOSE will be determined by patient or surrogate telephone interview, based on a structured interview of 19 questions. The GOSE is a scale of 1-8 where 1 - deceased, 2 - vegetative state, 3 - low severe disability, 4 - upper severe disability, 5 - low moderate disability, 6 -upper moderate disability, 7 - low good recovery, 8 - upper good recovery.","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age \\> 18\n2. Head CT evidence of subarachnoid hemorrhage\n3. Digital subtraction cerebral angiography or CT angiogram documenting the presence of a cerebral aneurysm.\n\nExclusion Criteria:\n\n1. Symptom onset compatible with SAH of \\> 3 days prior to admission to OHSU\n2. Absence of an indwelling external ventricular drain\n3. Administration of any of the following inducers/inhibitors of CYP3A4: ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, telithromycin, chloramphenicol, ketoconazole, itraconazole, nefazodone, cobicistat or enzalutamide.\n4. Suspected or confirmed pregnancy\n5. Preexisting severe neurologic deficit or condition\n6. Chronic renal failure requiring dialysis\n7. Severe terminal disease with life expectancy \\<6 months\n8. Unable to read or understand written or spoken English or Spanish\n9. Refusal of informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Ross Martini, MD","affiliation":"Oregon Health and Science University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Oregon Health & Science University","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}}]},"referencesModule":{"references":[{"pmid":"34873674","type":"DERIVED","citation":"Martini RP, Siler D, Cetas J, Alkayed NJ, Allen E, Treggiari MM. A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2022 Jun;36(3):905-915. doi: 10.1007/s12028-021-01398-8. Epub 2021 Dec 6."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"FG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"1 subject in the placebo group died on study day 9 after having received 9 of 10 doses of study drug. Data is included for this subject throughout the analysis","groups":[{"id":"BG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"BG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.2","spread":"11.2"},{"groupId":"BG001","value":"60.4","spread":"11.4"},{"groupId":"BG002","value":"60.8","spread":"11.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"17"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.8","spread":"6.6"},{"groupId":"BG001","value":"27.7","spread":"4.7"},{"groupId":"BG002","value":"28.2","spread":"5.6"}]}]}]},{"title":"Smoking","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Never/Passive Smoker","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}]},{"title":"Active Smoker","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]},{"title":"Former Smoker","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"History of Hypertension","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"15"}]}]}]},{"title":"History of Seizure","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"History of Prior Brain Aneurysm","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Pre-Admission Antihypertensives","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"11"}]}]}]},{"title":"Pre-Admission Anticoagulants","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Pre-Admission Antiplatelet Agents","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Pre-Admission Statins","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Pre-Admission Antidiabetic Agents","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Hunt and Hess Scale","description":"The Hunt and Hess scale is a grading system used to classify the severity of a subarachnoid hemorrhage based on the patient's clinical condition.\n\nDescription:\n\n1. - Asymptomatic, mild headache, slight nuchal rigidity\n2. - Moderate to severe headache, nuchal rigidity, no neurologic deficit other than cranial nerve palsy\n3. - Drowsiness / confusion, mild focal neurologic deficit\n4. - Stupor, moderate-severe hemiparesis\n5. - Coma, decerebrate posturing","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3.0","spread":".94"},{"groupId":"BG001","value":"3.0","spread":"1.0"},{"groupId":"BG002","value":"3.0","spread":".94"}]}]}]},{"title":"Modified Fisher Grade","description":"The modified Fisher scale is a method for grading subarachnoid hemorrhage (SAH) severity seen on non-contrast CT. The risk of vasospasm increases with each grade of the modified Fisher scale.\n\ngrade 0: no visible SAH or intraventricular hemorrhage (IVH) grade 1: thin SAH, no IVH, grade 2: thin focal or diffuse SAH with IVH grade 3: thick focal or diffuse SAH without IVH grade 4: thick focal or diffuse SAH, IVH present","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3.9","spread":".32"},{"groupId":"BG001","value":"3.7","spread":".71"},{"groupId":"BG002","value":"3.8","spread":".54"}]}]}]},{"title":"Glasgow Coma Scale at Randomization","description":"The Glasgow coma scale is used to assess responsiveness. The initial score correlates with the severity of brain injury and prognosis. The Glasgow Coma Scale provides a score in the range 3-15 and the sum of eye opening, motor and verbal responses. A higher score indicates less severe brain injury.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13.3","spread":"2.7"},{"groupId":"BG001","value":"10.7","spread":"3.6"},{"groupId":"BG002","value":"12.1","spread":"3.3"}]}]}]},{"title":"Location of Aneurysm","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Anterior Cerebral Artery/Branches","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]},{"title":"Middle Cerebral/Internal Carotid Artery/Branches","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]},{"title":"Posterior Cerebral Artery/Branches","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Vertebrobasilar System","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Treatment of Aneursym","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Craniotomy","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]},{"title":"Endovascular","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]},{"title":"Unsecured","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Baseline Aspartate Aminotransferase","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units/liter","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22.7","spread":"5.7"},{"groupId":"BG001","value":"25.5","spread":"11.8"},{"groupId":"BG002","value":"24.1","spread":"9.0"}]}]}]},{"title":"Baseline Aanine Transaminase","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units/liter","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27.5","spread":"13.4"},{"groupId":"BG001","value":"24.4","spread":"15.7"},{"groupId":"BG002","value":"26.1","spread":"14.2"}]}]}]},{"title":"Baseline QTc Interval","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"milliseconds","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"451.5","spread":"24.3"},{"groupId":"BG001","value":"456.4","spread":"31.5"},{"groupId":"BG002","value":"453.2","spread":"27.0"}]}]}]},{"title":"Admitted Intubated","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Adverse Events","description":"Summary tables and listings will be provided for all reported adverse events, defined as adverse events that start on or after the first administration of study drug. The reported adverse event term will be assigned a standardized preferred term.\n\nAdverse events will be summarized based on the number and percentage of patients experiencing the event. In the event a patient experiences repeat episodes of the same adverse event, then the event with the highest severity grade and strongest causal relationship to study treatment will be used for purposes of incidence tabulations.\n\nAll deaths will be reported in a patient listing, which will include the primary cause of death and the number of days between the date of the last dose of study drug and death.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"90 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Venous Thromboembolism","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Myocardial Infarction","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Seizure","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Any Documented Infection","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}]},{"title":"Cerebral Salt Wasting","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Leukopenia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Aneurysm Rebleed","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Acute Respiratory Distress Syndrome","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Death","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Study Day 7 and Study Day 10 Serum and CSF EET/ Dihyroxyeicosatrienoic (DHET) Ratio, by Mass Spectroscopic Analysis (ng/mL)","description":"Day 7 and day 10 serum EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected blood samples.\n\nDay 7 and day 10 CSF EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected CSF samples.","populationDescription":"Missing data occurred due to no sample collection from the CSF in patients who had external ventricular drains removed as part of their standard ICU care, prior to the study visit for sample collection. Missing serum samples are the result of one patient in the placebo group who died prior to sample collection visit, and multiple unsuccessful attempts at blood collection from another patient.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ration","timeFrame":"10 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Study day 7 CSF 14,15-EET/DHET ratio","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":".17","spread":".07"},{"groupId":"OG001","value":".19","spread":".16"}]}]},{"title":"Study day 10 CSF 14,15-EET/DHET ratio","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":".45","spread":".78"},{"groupId":"OG001","value":".52","spread":"1.04"}]}]},{"title":"Study day 7 serum 14,15-EET/DHET ratio","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":".30","spread":".11"},{"groupId":"OG001","value":".12","spread":".03"}]}]},{"title":"Study day 10 serum 14,15-EET/DHET ratio","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":".27","spread":".07"},{"groupId":"OG001","value":".12","spread":".02"}]}]}]},{"type":"SECONDARY","title":"Study Day 7 and Study Day 10 Serum Epoxyoctadecenoic Acid (EPOME) to Dihydroxyoctadec-12-enoic Acid (DPOME) Ratio, by Mass Spectroscopic Analysis (ng/mL)","description":"Study day 7 and study day 10 serum epoxyoctadecenoic acid (EPOME) to dihydroxyoctadec-12-enoic acid (DPOME) ratio, will be measure by mass spectroscopic analysis of collected blood samples.","populationDescription":"Missing data occurred due to no sample collection from the CSF in patients who had external ventricular drains removed as part of their standard ICU care, prior to the study visit for sample collection. Missing serum samples are the result of one patient in the placebo group who died prior to sample collection visit, and multiple unsuccessful attempts at blood collection from another patient.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ration","timeFrame":"10 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Day 7 serum 12,13 EpOME/DiHOME ratio","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"4.3"},{"groupId":"OG001","value":"1.8","spread":".92"}]}]},{"title":"Day 10 serum 12,13 EpOME/DiHOME ratio","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"7.1"},{"groupId":"OG001","value":"1.7","spread":".90"}]}]}]},{"type":"SECONDARY","title":"Serum Biomarkers of Endothelial Injury From Blood Samples Obtained on Study Day 7 and Study Day 10","description":"The following serum biomarkers will be obtained from collected blood samples by Luminex assay: e-selectin, p-selectin, Vascular cell adhesion marker (VCAM-1), Platelet endothelial cell adhesion marker (PECAM-1, CD31), intercellular adhesion molecule (ICAM-1).","populationDescription":"Missing data occurred due to no sample collection from the CSF in patients who had external ventricular drains removed as part of their standard ICU care, prior to the study visit for sample collection. Missing serum samples are the result of one patient in the placebo group who died prior to sample collection visit, and multiple unsuccessful attempts at blood collection from another patient.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"10 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Serum Day 7 ICAM","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"7.5"},{"groupId":"OG001","value":"8.3","spread":"6.8"}]}]},{"title":"Serum Day 10 ICAM","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"27"},{"groupId":"OG001","value":"6.7","spread":"6.6"}]}]},{"title":"Serum Day 7 VCAM","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"3.0"},{"groupId":"OG001","value":"7.9","spread":"2.0"}]}]},{"title":"Serum Day 10 VCAM","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"2.9"},{"groupId":"OG001","value":"7.9","spread":"2.1"}]}]},{"title":"Serum Day 7 PECAM-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":".56"},{"groupId":"OG001","value":"1.7","spread":".90"}]}]},{"title":"Serum Day 10 PECAM-1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":".90"},{"groupId":"OG001","value":"1.6","spread":".65"}]}]},{"title":"Serum Day 7 E-Selectin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":"25.3"},{"groupId":"OG001","value":"48.0","spread":"33.0"}]}]},{"title":"Serum Day 10 E-Selectin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":"23.8"},{"groupId":"OG001","value":"44.7","spread":"30.3"}]}]},{"title":"Serum Day 7 P-Selectin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":".83"},{"groupId":"OG001","value":"1.1","spread":".28"}]}]},{"title":"Serum Day 10 P-Selectin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":".90"},{"groupId":"OG001","value":"2.0","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"CSF Biomarkers of Neuroinflammation, From Blood Samples Obtained on Study Day 7 and Study Day 10","description":"The following CSF biomarker will be obtained from collected CSF samples by Luminex assay: Tumor necrosis factor alpha (TNF-α) (pg/mL), Interleukin 1β (IL-1β) (pg/mL), Interferon gamma (IFN-γ) (pg/mL), Interleukin 6 (IL-6) (pg/mL), Interleukin 8 (IL-8) (pg/mL), Monocyte chemoattractant protein 1 (MCP-1) (pg/mL)","populationDescription":"Missing data occurred due to no sample collection from the CSF in patients who had external ventricular drains removed as part of their standard ICU care, prior to the study visit for sample collection. Missing serum samples are the result of one patient in the placebo group who died prior to sample collection visit, and multiple unsuccessful attempts at blood collection from another patient.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg / mL","timeFrame":"10 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"CSF Day 7 IFN-gamma","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.0"},{"groupId":"OG001","value":"4.6","spread":"6.8"}]}]},{"title":"CSF Day 10 IFN-gamma","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":".84"},{"groupId":"OG001","value":"5.8","spread":"12.9"}]}]},{"title":"CSF Day 7 IL-1b","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":".82"},{"groupId":"OG001","value":"5.0","spread":"9.6"}]}]},{"title":"CSF Day 10 IL-1b","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":".50"},{"groupId":"OG001","value":"4.4","spread":"9.2"}]}]},{"title":"CSF Day 7 IL-6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2991.2","spread":"3420.0"},{"groupId":"OG001","value":"3417.9","spread":"4110.2"}]}]},{"title":"CSF Day 10 IL-6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2089.4","spread":"3248.4"},{"groupId":"OG001","value":"2051.6","spread":"3570.7"}]}]},{"title":"CSF Day 7 IL-8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1652.4","spread":"1374.4"},{"groupId":"OG001","value":"3971.0","spread":"3298.9"}]}]},{"title":"CSF Day 10 IL-8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1093.6","spread":"775.3"},{"groupId":"OG001","value":"1485.8","spread":"1002.2"}]}]},{"title":"CSF Day 7 TNF-alpha","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"2.6"},{"groupId":"OG001","value":"13.1","spread":"15.6"}]}]},{"title":"CSF Day 10 TNF-alpha","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"2.8"},{"groupId":"OG001","value":"8.1","spread":"9.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hospital Length of Stay in Days","description":"The hospital length of stay will be recorded in days, at the time of hospital discharge.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"90 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":"3.3"},{"groupId":"OG001","value":"28.8","spread":"19.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Discharge Disposition","description":"The disposition from the hospital in one of the following categories: home, home with services, rehab, long term acute care facility, skilled nursing facility, hospice, death","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"90 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"title":"Discharged to home","measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]},{"title":"Discharged to rehab, long term acute care facility, skilled nursing facility, hospice, death","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With New Stroke on Hospital Discharge Imaging","description":"The last head CT or other brain imaging to detect the presence of a new area of cerebral infarction will be reviewed at the time of hospital discharge. A cerebral infarction will be defined as a one identified on hospital discharge that was not present on imaging between 24-48 hours after aneurysm occlusion, and not attributable to other causes such as surgical clipping or endovascular treatment. Hypodensities resulting from extraventricular drains or residual intraparencyhmal hematomas will not be considered new strokes.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"90 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Modified Rankin Scale (mRS) at Hospital Discharge and 90 Day Follow up","description":"The mRS score will be determined by patient or surrogate interview, at both hospital discharge and 90 day follow up. Scores will be assigned based on the following: 0 - no symptoms, 1 - no significant disability, able to carry out all usual activities despite some symptoms, 2 - slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 - moderate disability, requires some help, but able to walk unassisted, 4 - moderately severe disability, unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 - severe disability, requires constant nursing care and attention, bedridden, incontinent, 6 - deceased.","populationDescription":"One subject in GSK2256294 group lost to followup","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"90 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Hospital Discharge mRS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.5"},{"groupId":"OG001","value":"4.1","spread":"1.4"}]}]},{"title":"90 day follow-up mRS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.6"},{"groupId":"OG001","value":"3.3","spread":"1.7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Extended Glasgow Outcome Scale (GOSE) Score at 90 Day Follow up","description":"At 90 day follow up, the GOSE will be determined by patient or surrogate telephone interview, based on a structured interview of 19 questions. The GOSE is a scale of 1-8 where 1 - deceased, 2 - vegetative state, 3 - low severe disability, 4 - upper severe disability, 5 - low moderate disability, 6 -upper moderate disability, 7 - low good recovery, 8 - upper good recovery.","populationDescription":"Missing data due to one subject in the GSK2256294 lost to followup","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"90 days","groups":[{"id":"OG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days."},{"id":"OG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"2.4"},{"groupId":"OG001","value":"4.1","spread":"2.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse event data was collected up to 90 days after hospital discharge at the time of followup phone visit","eventGroups":[{"id":"EG000","title":"GSK2256294","description":"10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.\n\nGSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":4,"seriousNumAtRisk":10,"otherNumAffected":0,"otherNumAtRisk":10},{"id":"EG001","title":"Placebo","description":"10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.\n\nPlacebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days.","deathsNumAffected":1,"deathsNumAtRisk":9,"seriousNumAffected":5,"seriousNumAtRisk":9,"otherNumAffected":0,"otherNumAtRisk":10}],"seriousEvents":[{"term":"Delayed Cerebral Ischemia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":9}]},{"term":"Rebleed of Unsecured Aneurysm","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":9}]},{"term":"Aspiration Pneumonia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":9}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":9}]},{"term":"Deep Vein Thrombosis","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":9}]},{"term":"Central Line Associated Bloodstream Infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":9}]},{"term":"Acute Respiratory Distress Syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":9}]},{"term":"Pseudomonas Ventriculitis, Bacteremia, Urinary Tract Infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":9}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":9}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":true},"pointOfContact":{"title":"Ross Martini","organization":"Oregon Health and Science University","email":"martinir@ohsu.edu","phone":"4013386803"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-11-29","uploadDate":"2020-10-01T16:15","filename":"Prot_SAP_000.pdf","size":581770}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2020-10-26","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000013345","term":"Subarachnoid Hemorrhage"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000020301","term":"Vasospasm, Intracranial"},{"id":"D000006470","term":"Hemorrhage"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020300","term":"Intracranial Hemorrhages"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000020521","term":"Stroke"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M9246","name":"Hemorrhage","asFound":"Hemorrhage","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemia","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Ischemia","relevance":"HIGH"},{"id":"M15825","name":"Subarachnoid Hemorrhage","asFound":"Subarachnoid Hemorrhage","relevance":"HIGH"},{"id":"M5484","name":"Brain Ischemia","asFound":"Cerebral Ischemia","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M21804","name":"Vasospasm, Intracranial","asFound":"Vasospasm, Cerebral","relevance":"HIGH"},{"id":"M21803","name":"Intracranial Hemorrhages","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"}]}},"hasResults":true}